Antony Currie and Rob Cox explain how the $160 bln pharma merger gets around recent U.S. attempts to stop inversion deals – and why it may prompt policymakers to reform the tax code.
from Reuters Video: Breakingviews http://ift.tt/1X9C4KD
via IFTTT
No comments:
Post a Comment